ebastine has been researched along with idelalisib in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Angelone, T; Avolio, E; Barbieri, A; Botti, G; De Bartolo, A; De Lorenzo, A; Gualtieri, P; Palma, G; Pasqua, T; Rocca, C; Silvestri, G | 1 |
1 review(s) available for ebastine and idelalisib
Article | Year |
---|---|
PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Butyrophenones; Class I Phosphatidylinositol 3-Kinases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Inflammation; Interleukin-6; Molecular Targeted Therapy; Pandemics; Peptidyl-Dipeptidase A; Piperidines; Pneumonia, Viral; Purines; Quinazolinones; SARS-CoV-2 | 2020 |